Key clinical studies on eszopiclone 2 mg
1. Short-term efficacy (2-week study)
- A randomized controlled trial found that eszopiclone 2 mg significantly improved sleep compared with placebo.
- Benefits included:
- Faster time to fall asleep
- Longer total sleep time
- Better sleep quality and daytime alertness
- It was well tolerated, with the most common side effect being an unpleasant taste.
👉 Conclusion: 2 mg works for both sleep onset and sleep maintenance, especially in older adults.
2. Longer-term study (12 weeks)
- A 12-week placebo-controlled trial showed:
- Increased total sleep time by about +60 minutes on average
- Reduced time to fall asleep and night awakenings
- Improved daytime functioning
- No rebound insomnia after stopping the drug
- Common side effects: headache, bad taste, mild infections
👉 Conclusion: Sustained benefit over 3 months, not just short-term.
3. Long-term safety (24-week study)
- A 6-month study (including 2 mg doses) found:
- Continued improvement in sleep quality and daytime function
- No evidence of dependence or rebound insomnia
- Side effects were common but generally mild (taste disturbance most frequent)
👉 Conclusion: Can be effective and relatively safe even with longer use under supervision.
4. Meta-analysis of randomized trials
- A systematic review confirmed that eszopiclone:
- Improves sleep latency (falling asleep)
- Improves sleep duration and quality
- Works across different patient groups with insomnia
5. General pharmacology and effects
- Eszopiclone is a non-benzodiazepine hypnotic acting on GABA receptors
- Rapid onset (peak levels ~1 hour)
- Proven to improve:
- Sleep induction
- Sleep maintenance
- Next-day functioning
🇬🇧 Notes about the UK context
- Eszopiclone is less commonly prescribed in the UK compared to its related drug zopiclone
- UK guidelines (e.g., NHS practice) tend to favor:
- Short-term use of hypnotics
- Alternatives like CBT for insomnia
- Eszopiclone may still be considered similar pharmacologically to zopiclone